Tofacitinib reduced death or respiratory failure at 28 d in patients hospitalized with COVID-19 pneumonia

1 October 2021

journal article
editorial
Published by American College of Physicians in Annals of Internal Medicine

Vol. 174 (10), JC111
https://doi.org/10.7326/acpj202110190-111

Abstract

Source Citation Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385:406-15. 34133856 Clinical Impact Ratings Hospitalists: 6 out of 7 Infectious Disease: 6 out of 7 Critical Care: 5 out of 7 Pulmonology: 5 out of 7

This publication has 4 references indexed in Scilit:

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet, 2021
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
The New England Journal of Medicine, 2021
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
The New England Journal of Medicine, 2021
Dexamethasone in Hospitalized Patients with Covid-19
The New England Journal of Medicine, 2021

Cited by 3 articles